Aclarion, Inc. Warrant - ACONW STOCK NEWS

Welcome to our dedicated page for Aclarion Warrant news (Ticker: ACONW), a resource for investors and traders seeking the latest updates and insights on Aclarion Warrant stock.

Aclarion, Inc. (Nasdaq: ACON, ACONW) is a pioneering healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The company's flagship product, Nociscan, is a revolutionary SaaS platform designed to noninvasively help physicians distinguish between painful and nonpainful discs in the spine, providing essential insights into the location of chronic low back pain. This innovative solution transforms complex MRS data into clear, actionable reports for medical professionals, enhancing patient diagnosis and treatment strategies.

Aclarion's business model is centered around delivering Nociscan reports to medical professionals, with all revenues generated from contracts with customers in the United States. Notably, Aclarion has seen a significant acceleration in the pace of Nociscan orders, with the last 250 scans being completed 2.5 times faster than the first 250. The company anticipates further growth as additional MRI scanners, including those from Siemens and Philips, are activated for key opinion leader surgeons.

Recent achievements include the completion of 1,000 commercial Nociscan exams, with 36% of these studies conducted in the past year alone. This milestone underscores the growing adoption of Aclarion's strategy and its journey towards becoming the standard of care in the industry. The company's patent portfolio is robust, featuring 22 U.S. patents, 17 international patents, and several pending applications, including exclusive licenses from Regents of the University of California.

Aclarion has also initiated strategic partnerships, such as the agreement with Alphatec Spine, Inc., to integrate Nociscan within ATEC’s AlphaInformatiX platform. This partnership aims to enhance clinical outcomes and reduce procedural costs by providing surgeons with comprehensive data on one platform.

Financially, Aclarion has strengthened its position through several financing transactions, reducing debt and increasing available cash. These funds will support key initiatives, including the CLARITY trial, which aims to validate the superior surgical outcomes associated with Nociscan.

With a commitment to advancing the field of augmented intelligence and MR spectroscopy, Aclarion continues to lead the way in addressing the global healthcare problem of chronic low back pain, impacting millions worldwide.

01/22/2024 08:00 AM

News

Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD

Rhea-AI Summary

Aclarion, Inc. announces the availability of Nociscan, their diagnostic solution for chronic low back pain, at the Barrow Neurological Institute in Phoenix, AZ. Dr. Juan Uribe, a renowned neurosurgeon, is now the 3rd key opinion leader with access to the diagnostic center. Nociscan aims to help physicians identify the location of chronic low back pain noninvasively through chemical biomarkers and proprietary algorithms. The activation of the Phoenix market is expected to support scan volume growth in 2024.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

01/17/2024 08:00 AM

News

Aclarion Announces Updated Product Release That Expands MRI Scanner Access for Nociscan Solution

Rhea-AI Summary

Aclarion, Inc. (Nasdaq: ACON, ACONW) announced the product release of Nociscan 2.6, expanding accessibility on the worldwide MRI market. This new release includes support for additional leading MRI scanners beyond those manufactured by Siemens, a major milestone towards making Nociscan available on the leading MRI machines of all manufacturers. The company aims to improve the lives of millions of patients suffering from degenerative spine disease and low back pain.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

01/08/2024 08:00 AM

News

Aclarion and ATEC Execute Strategic Partnership Agreement to Advance Commercialization of Nociscan

Rhea-AI Summary

Aclarion, Inc. (Nasdaq: ACON, ACONW) partners with Alphatec Spine, Inc. (Nasdaq: ATEC) to integrate Aclarion’s Nociscan technology, the first augmented intelligence platform to measure pain biomarkers in the lumbar spine, into ATEC’s AlphaInformatiX platform. The partnership aims to improve clinical outcomes and reduce procedural costs for patients with chronic low back pain, leveraging ATEC’s surgeon network and providing ATEC with exclusive distribution rights for Nociscan. Aclarion’s published trials confirm the comparative advantage of Nociscan in achieving differentiated surgical outcomes, with a peer-reviewed publication demonstrating an 85% success rate at two years for discogenic low back pain surgeries consistent with Nociscan-identified discs, compared to 63% for inconsistent treatment strategies.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

01/02/2024 12:00 PM

News

Aclarion Announces Reverse Stock Split

Rhea-AI Summary

Aclarion, Inc. (Nasdaq: ACON, ACONW) announced a 1-for-16 reverse stock split effective before market open on January 4, 2024, to meet Nasdaq listing standards. The split will increase the per share price and bid price of its common stock above the $1.00 required by Nasdaq’s Minimum Bid Price Rule.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

11/27/2023 08:00 AM

News

Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams

Rhea-AI Summary

Aclarion, Inc. (ACON) has completed 1,000 commercial Nociscan exams, with the pace of commercial adoption accelerating. The company's CEO, Brent Ness, highlighted the achievement and the strategy that led to it. Aclarion's Chief Strategy Officer, Ryan Bond, emphasized the importance of Nociscan in transforming complex data into individualized biomarker reports for chronic low back pain patients. The company holds a disruptive innovation with a strong patent portfolio and aims to address the high healthcare spending on low back and neck pain in the US.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

11/08/2023 08:00 AM

News

Aclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan Adoption

Rhea-AI Summary

Aclarion (ACON) successfully enrolls 10 leading spine surgery KOLs to drive Nociscan to standard of care for identifying discogenic low back pain. The company will activate MRIs for each KOL surgeon to expand Nociscan access and demonstrate clinical outcome improvements to payers, with initial scan volume data to be released by the end of the year. The recruitment of renowned KOL surgeons is a critical step in establishing Nociscan as the standard of care for diagnosing and treating low back pain.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

11/06/2023 08:00 AM

News

Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD

Rhea-AI Summary

Aclarion, a healthcare technology company, has announced that Dr. Roger Hartl, a renowned neurosurgeon, will advise the company as a key opinion leader (KOL) nationally. Aclarion's Nociscan solution helps physicians identify the location of chronic low back pain noninvasively. Dr. Hartl will have access to an MRI center authorized to perform Nociscans in New York City, adding to the existing site in Denver. Aclarion plans to report on Nociscan volumes before the end of the year and include this metric in quarterly reporting from 2024.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

11/01/2023 08:00 AM

News

Aclarion Presents at the NIH HEAL Initiative Fall Meeting

Rhea-AI Summary

Aclarion, a healthcare technology company, announced that its Nociscan platform will be presented at the NIH HEAL Initiative BACPAC Research Program. Nociscan is a decision support tool that helps physicians identify the location of chronic low back pain. It is being utilized in two leading low back pain trials within the HEAL Initiative. The NIH HEAL Initiative aims to address the opioid crisis by funding research on chronic low back pain.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

10/25/2023 08:30 AM

News

Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver

Rhea-AI Summary

Porter Hospital in Denver has become the first facility to offer Nociscan technology for chronic low back pain patients. The technology measures biomarkers to pinpoint the source of pain and has been shown to improve patient outcomes and reduce costs. Aclarion, the healthcare technology company behind Nociscan, is expanding its footprint in Colorado with AdventHealth Porter. The addition of Nociscan to the hospital's diagnostic evaluation is expected to improve treatment strategies and provide personalized biomarker data to physicians.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

10/24/2023 08:45 AM

News

Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting

Rhea-AI Summary

Aclarion's Nociscan cost-effectiveness study showcased at medical decision making meeting

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

FAQ

What is the current stock price of Aclarion Warrant (ACONW)?

The current stock price of Aclarion Warrant (ACONW) is $0.0298 as of January 29, 2025.

What does Aclarion, Inc. do?

Aclarion, Inc. is a healthcare technology company that uses Magnetic Resonance Spectroscopy and proprietary biomarkers to optimize clinical treatments. Its main product, Nociscan, helps identify painful and nonpainful discs in the spine.

What is Nociscan?

Nociscan is a SaaS platform developed by Aclarion that uses Magnetic Resonance Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine.

How does Aclarion generate revenue?

Aclarion generates revenue from the delivery of Nociscan reports to medical professionals. All revenues are derived from contracts with customers in the United States.

What recent achievements has Aclarion made?

Aclarion recently completed 1,000 commercial Nociscan exams and has seen a significant increase in the pace of orders. The company's patent portfolio has also expanded, and it has entered into strategic partnerships to enhance its product offerings.

What strategic partnerships has Aclarion formed?

Aclarion has formed a strategic partnership with Alphatec Spine, Inc. to integrate Nociscan within ATEC’s AlphaInformatiX platform, aiming to improve clinical outcomes and reduce procedural costs.

What is the CLARITY trial?

The CLARITY trial is a prospective, multicenter, randomized clinical trial initiated by Aclarion to validate the superior surgical outcomes associated with Nociscan technology.

How does Nociscan work?

Nociscan receives Magnetic Resonance Spectroscopy data from an MRI machine, extracts and quantifies chemical biomarkers associated with disc pain, and uses proprietary algorithms to indicate if a disc may be a source of pain.

What is Aclarion's market focus?

Aclarion is first addressing the chronic low back pain market with its Nociscan platform, aiming to become the standard of care for diagnosing and treating this condition.

What financial steps has Aclarion taken recently?

Aclarion has completed several financing transactions, raising proceeds that have reduced debt and increased available cash to support key initiatives, including the CLARITY trial.

How does Aclarion's technology benefit physicians?

Aclarion's Nociscan provides physicians with critical insights into the location of a patient’s low back pain, enhancing clarity and optimizing treatment strategies through noninvasive means.